AdaptHealth Corp. (NASDAQ:AHCO) Shares Sold by Royce & Associates LP

Key Points

• Royce & Associates LP reduced its stake in AdaptHealth Corp. by 3.7%, now owning approximately 0.72% of the company, worth $10,472,000.
• AdaptHealth's stock has a market capitalization of $1.27 billion and is currently priced at $9.44, marking a 2.4% increase.
• Several analysts have adjusted their target price for AdaptHealth, with Royal Bank of Canada and Truist Financial both lowering their targets from $14.00 to $13.00, while maintaining a "buy" rating.

Royce & Associates LP decreased its stake in AdaptHealth Corp. (NASDAQ:AHCO - Free Report) by 3.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 966,075 shares of the company's stock after selling 36,680 shares during the quarter. Royce & Associates LP owned approximately 0.72% of AdaptHealth worth $10,472,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. GAMMA Investing LLC grew its stake in shares of AdaptHealth by 175.2% during the 1st quarter. GAMMA Investing LLC now owns 7,473 shares of the company's stock worth $81,000 after purchasing an additional 4,758 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in AdaptHealth during the first quarter worth $114,000. Legato Capital Management LLC acquired a new stake in AdaptHealth during the first quarter valued at $167,000. Guggenheim Capital LLC increased its holdings in AdaptHealth by 10.1% in the fourth quarter. Guggenheim Capital LLC now owns 16,613 shares of the company's stock valued at $158,000 after buying an additional 1,525 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of AdaptHealth in the fourth quarter worth about $169,000. 82.67% of the stock is owned by institutional investors and hedge funds.

AdaptHealth Stock Up 2.4%

AHCO opened at $9.44 on Friday. The company has a market cap of $1.27 billion, a PE ratio of 16.56, a price-to-earnings-growth ratio of 0.89 and a beta of 1.63. AdaptHealth Corp. has a twelve month low of $7.11 and a twelve month high of $11.73. The company has a 50-day moving average price of $9.03 and a 200 day moving average price of $9.39. The company has a quick ratio of 1.07, a current ratio of 1.29 and a debt-to-equity ratio of 1.25.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Royal Bank Of Canada dropped their target price on AdaptHealth from $14.00 to $13.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. Truist Financial cut their price objective on AdaptHealth from $14.00 to $13.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $13.40.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.